Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

OUTLINE: Patients receive axatilimab IV over 30 minutes on days 1 and 15 of cycles 1-6 and then on day 1 of remaining cycles. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection throughout the study. Additionally, patients may undergo optional skin biopsies and optional skin flexibility assessments throughout the study. After completion of study treatment, patients are followed up at 30 days then for up to 2 years.